Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 13, 2009

French Authorities Approve Six-Month Formulation of Debiopharm and Ipsen’s Prostate Cancer Drug

  • Debiopharm and its European licensee, Ipsen, confirmed French regulatory clearance for the six-monthly sustained-release formulation of the LHRH agonist, Decapeptyl®, for locally advanced and metastatic prostate cancer. Ipsen says that it expects to launch the drug in France during the first quarter of 2010.

    The six-monthly formulation was approved in October via the European decentralized registration procedure in nine countries: Germany (the reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain, and The Netherlands. Regulatory submissions in Portugal, the U.K., Ireland, Italy, Romania, and Lithuania have been filed as national line extensions to existing approvals for other Decapeptyl formulations.

    The therapy is already available in monthly and quarterly sustained-release formulations as well as a daily formulation. It is sanctioned in various markets including the U.S. for the treatment of advanced prostate cancer as well as for indications in endometriosis, precocious puberty, IVF, and uterine fibroids. Debiopharm says worldwide sales by its licensees are over $400 million.


Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »